References

  1. Stone, Edmund (1763) An Account of the Success of the Bark of the Willow in the Cure of Agues. Philosophical Transactions of the Royal Society 53:195-200
  2. Fleming, Alexander (1929) On the antibacterial action of cultures of a Penicillium, with special reference to their use in isolation of B.~influenzae. British Journal of Experimental Pathology 10:226-236
  3. Brunel, J. (1951) Antibiosis from Pasteur to Fleming. J Hist Med Allied Sci 6:287-301
  4. Ehrlich, Paul (1908) Partial cell functions. web page.
  5. Bickerton, R. K. (1963) The response of isolated strips of cat spleen to sympathomimetic drugs and their antagonists. J Pharmacol Exp Ther 142:99-9110
  6. Shapiro, David A. et al. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411
  7. Berg, K. A. et al. (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-9104
  8. Strickland, S. and Loeb, J. N. (1981) Obligatory separation of hormone binding and biological response curves in systems dependent upon secondary mediators of hormone action. Proc Natl Acad Sci U S A 78:1366-1370
  9. Brown, L. et al. (1992) Spare receptors for β-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart. J Cardiovasc Pharmacol 19:222-232
  10. Katzung, Bertram G. (2001) Basic and Clinical Pharmacology (McGraw-Hill).
  11. Aller, Stephen G. et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718-1722
  12. Dawson, Roger J. P. and Locher, Kaspar P. (2007) Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett 581:935-938
  13. Bihorel, Sébastien et al. (2007) Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res 24:1720-1728
  14. Tröger, Uwe et al. (2005) Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood-brain barrier. BMJ 331:613
  15. Wada, D. R. et al. (1997) Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. Anesthesiology 87:884-899
  16. Frenia, M. L. et al. (1996) Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination. J Toxicol Clin Toxicol 34:169-175
  17. Zuccato, Ettore et al. (2005) Cocaine in surface waters: a new evidence-based tool to monitor community drug abuse. Environ Health 4:14
  18. Brunton, L. L. et al. (2005) Goodman and Gilman's The pharmacological basis of therapeutics (McGraw Hill).
  19. He, K. et al. (1998) Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11:252-259
  20. Ekroos, Marika and Sjögren, Tove (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A 103:13682-13687
  21. Chrencik, Jill E. et al. (2005) Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol 19:1125-1134
  22. Bauer, Jacob et al. (2007) A structural gap in Dpo4 supports mutagenic bypass of a major benzo[a]pyrene dG adduct in DNA through template misalignment. Proc Natl Acad Sci U S A 104:14905-14910
  23. Goedde, H. W. et al. (1964) Studies on pharmacogenetics. I. The enzymatic acetylation of isonicotinic acid hydrazide (INH). Biochem Pharmacol 13:1671-1675
  24. Rashid, J. R. et al. (1992) Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital. East Afr Med J 69:406-408
  25. Golka, Klaus et al. (2002) The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol Lett 128:229-241
  26. Mattano, S. S. et al. (1989) Purification and biochemical characterization of hepatic arylamine N-acetyltransferase from rapid and slow acetylator mice: identity with arylhydroxamic acid N,O-acyltransferase and N-hydroxyarylamine O-acetyltransferase. Mol Pharmacol 35:599-609
  27. Fu, Yue et al. (2005) Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954. Biochem Biophys Res Commun 336:332-338
  28. Hein, Peter et al. (2006) Gs activation is time-limiting in initiating receptor-mediated signaling. J Biol Chem 281:33345-33351
  29. Gether, U. et al. (1993) Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist. Nature 362:345-348
  30. Hubbell, Wayne L. et al. (2003) Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv Protein Chem 63:243-290
  31. Arnis, S. et al. (1994) A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin. J Biol Chem 269:23879-23881
  32. Chackalamannil, Samuel et al. (2005) Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem 48:5884-5887
  33. Galvez, T. et al. (2001) Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO J 20:2152-2159
  34. Ma, Amy W. -. S. et al. (2007) Recovery of oligomers and cooperativity when monomers of the M2 muscarinic cholinergic receptor are reconstituted into phospholipid vesicles. Biochemistry 46:7907-7927
  35. Rajeswaran, W. G. et al. (2001) Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists. J Med Chem 44:4563-4576
  36. Waldhoer, Maria et al. (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A 102:9050-9055
  37. Dalpiaz, Alessandro et al. (2012) A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approach. Mol Pharm 9:591-604
  38. Matkovich, Scot J. et al. (2006) Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and β-adrenergic signaling. Circ Res 99:996-991003
  39. Shenoy, Sudha K. et al. (2006) beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 281:1261-1273
  40. Piersol, George A. (1908) Human Anatomy (Lippincott).
  41. dos Reis, Almiro Jr (2009) Sigmund Freud (1856-1939) and Karl Kö{}ller (1857-1944) and the discovery of local anesthesia. Rev Bras Anestesiol 59:244-257
  42. Zamponi, G. W. and French, R. J. (1993) Dissecting lidocaine action: diethylamide and phenol mimic separate modes of lidocaine block of sodium channels from heart and skeletal muscle. Biophys J 65:2335-2347
  43. Roy, M. et al. (1996) HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94:817-823
  44. Huang, Luping et al. (2004) NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino) ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther 309:193-199
  45. SoRelle, R. (1998) Withdrawal of Posicor from market. Circulation 98:831-832
  46. Hannon, Heidi E. and Atchison, William D. (2013) Omega-conotoxins as experimental tools and therapeutics in pain management. Mar Drugs 11:680-699
  47. Skou, J. C. (1957) The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochim Biophys Acta 23:394-401
  48. Post, R. L. et al. (1972) Activation by adenosine triphosphate in the phosphorylation kinetics of sodium and potassium ion transport adenosine triphosphatase. J Biol Chem 247:6530-6540
  49. Forbush, B. (1987) Rapid release of 42K and 86Rb from an occluded state of the Na,K-pump in the presence of ATP or ADP. J Biol Chem 262:11104-11115
  50. Chiara, David C. et al. (2003) Identification of amino acids in the nicotinic acetylcholine receptor agonist binding site and ion channel photolabeled by 4-[(3-trifluoromethyl)-3H-diazirin-3-yl]benzoylcholine, a novel photoaffinity antagonist. Biochemistry 42:271-283
  51. Katz, B. and Thesleff, S. (1957) A study of the desensitization produced by acetylcholine at the motor end-plate. J Physiol 138:63-80
  52. Foster, Alan C. and Kemp, John A. (2006) Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol 6:7-17
  53. Sulzer, David et al. (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406-433
  54. Robinson, R. L. (1966) Stimulation of the release of catecholamines from isolated adrenal glands by tyramine. J Pharmacol Exp Ther 151:55-58
  55. Nilsson, Bengt-Olof et al. (2011) G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling. Br J Pharmacol 163:1131-1139
  56. Reddy, Doodipala Samba (2010) Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res 186:113-137
  57. Vayssière, B. M. et al. (1997) Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 11:1245-1255
  58. Janka-Junttila, Mirkka et al. (2006) The glucocorticoid RU24858 does not distinguish between transrepression and transactivation in primary human eosinophils. J Inflamm (Lond) 3:10
  59. King, Elizabeth M. et al. (2013) Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms. PLoS One 8:e53936
  60. Clapauch, Ruth et al. (2009) Total estradiol, rather than testosterone levels, predicts osteoporosis in aging men. Arq Bras Endocrinol Metabol 53:1020-1025
  61. Sanz-Rodríguez, Carlos E. et al. (2007) Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: kinetic and metabolic studies. J Biol Chem 282:12377-12387
  62. Pérez-Castrillón, José L. et al. (2007) Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 99:903-905
  63. Jaffrey, S. R. et al. (2001) Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol 3:193-197
  64. Chen, Zhiqiang et al. (2002) Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 99:8306-8311
  65. Minamiyama, Yukiko et al. (2007) Cytochrome P450 is responsible for nitric oxide generation from NO-aspirin and other organic nitrates. Drug Metab Pharmacokinet 22:15-19
  66. Schrammel, A. et al. (1998) Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione. Mol Pharmacol 54:207-212
  67. Cuzzocrea, Salvatore et al. (2002) Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol 453:119-129
  68. Langenbach, R. et al. (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83:483-492
  69. Morham, S. G. et al. (1995) Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83:473-482
  70. Rowlinson, Scott W. et al. (2003) A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem 278:45763-45769
  71. Serhan, Charles N. (2005) Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 73:141-162
  72. Loo, Y. H. (1974) Serotonin deficiency in experimental hyperphenylalaninemia. J Neurochem 23:139-147
  73. Woolf, L. I. (1986) The heterozygote advantage in phenylketonuria. Am J Hum Genet 38:773-775
  74. Kohn, Donald B. and Gaspar, H. Bobby (2017) How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).. Journal of clinical immunology -:n/a
  75. Joachims, Michelle L. et al. (2008) Inhibition of deoxynucleoside kinases in human thymocytes prevents dATP accumulation and induction of apoptosis. Nucleosides Nucleotides Nucleic Acids 27:816-820
  76. Löffler, W. et al. (1982) Influence of dietary purines on pool size, turnover, and excretion of uric acid during balance conditions. Isotope studies using 15N-uric acid. Res Exp Med (Berl) 181:113-123
  77. Mehlhaff, D. L. and Stein, D. S. (1996) Gout secondary to ritonavir and didanosine. AIDS 10:1744
  78. Choi, Hyon K. et al. (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277-1281
  79. Kishibe, Mari et al. (2010) Chronic tophaceous gout secondary to self-induced vomiting in anorexia nervosa. J Dermatol 37:578-580
  80. Heuckenkamp, P. U. and Zöllner, N. (1971) Fructose-induced hyperuricaemia. Lancet 1:808-809
  81. Oberhaensli, R. D. et al. (1987) Study of hereditary fructose intolerance by use of 31P magnetic resonance spectroscopy. Lancet 2:931-934
  82. Choi, Hyon K. and Curhan, Gary (2008) Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336:309-312
  83. Barranger, J. A. and O'Rourke, E. (2001) Lessons learned from the development of enzyme therapy for Gaucher disease. J Inherit Metab Dis 24 Suppl 2:89-96
  84. Colca, Jerry R. et al. (2013) Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)–relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One 8:e61551
  85. Divakaruni, Ajit S. et al. (2013) Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A 110:5422-5427
  86. Miller, Russell A. et al. (2013) Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494:256-260
  87. Palmer, Michael (2003) Efflux of cytoplasmically acting antibiotics from gram-negative bacteria: periplasmic substrate capture by multicomponent efflux pumps inferred from their cooperative action with single-component transporters. J Bacteriol 185:5287-5289
  88. Marquardt, J. L. et al. (1994) Kinetics, stoichiometry, and identification of the reactive thiolate in the inactivation of UDP-GlcNAc enolpyruvoyl transferase by the antibiotic fosfomycin. Biochemistry 33:10646-10651
  89. Goff, Donald C. (2012) D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr Bull 38:936-941
  90. Johnson, Jarrod W. et al. (2010) Cyclobutanone analogues of β-lactams revisited: insights into conformational requirements for inhibition of serine- and metallo-β-lactamases. J Am Chem Soc 132:2558-2560
  91. Sulton, Deley et al. (2005) Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 β-lactamase. Insights into the mechanism of inhibition. J Biol Chem 280:35528-35536
  92. Xie, Jian et al. (2011) A redesigned vancomycin engineered for dual D-Ala-D-ala And D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria. J Am Chem Soc 133:13946-13949
  93. Palmer, Adam C. and Kishony, Roy (2014) Opposing effects of target overexpression reveal drug mechanisms. Nat Commun 5:4296
  94. Muraih, Jawad K. et al. (2011) Oligomerization of daptomycin on membranes. Biochim Biophys Acta 1808:1154-1160
  95. Zhang, Tianhua et al. (2013) Mutual inhibition through hybrid oligomer formation of daptomycin and the semisynthetic lipopeptide antibiotic CB-182,462. Biochim Biophys Acta 1828:302-308
  96. Zhang, T. et al. (2014) Daptomycin forms cation- and size-selective pores in model membranes. Biochim Biophys Acta 1838:2425-2430
  97. Teerlink, T. et al. (1980) The action of pimaricin, etruscomycin and amphotericin B on liposomes with varying sterol content. Biochim Biophys Acta 599:484-492
  98. Walev, I. and Bhakdi, S. (1996) Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B. Antimicrob Agents Chemother 40:1116-1120
  99. Uhlemann, Anne-Catrin et al. (2005) A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol 12:628-629
  100. Luque-Ortega, Juan Román and Rivas, Luis (2007) Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob Agents Chemother 51:1327-1332
  101. Hoang, Anh N. et al. (2010) The neutral lipid composition present in the digestive vacuole of Plasmodium falciparum concentrates heme and mediates \gb-hematin formation with an unusually low activation energy. Biochemistry 49:10107-10116
  102. Kapishnikov, Sergey et al. (2012) Oriented nucleation of hemozoin at the digestive vacuole membrane in Plasmodium falciparum. Proc Natl Acad Sci U S A 109:11188-11193
  103. Gildenhuys, Johandie et al. (2013) The Single Crystal X-ray Structure of \gb-Hematin DMSO Solvate Grown in the Presence of Chloroquine, a \gb-Hematin Growth-Rate Inhibitor. J Am Chem Soc 135:1037-1047
  104. Müller, M. (1993) The hydrogenosome. J Gen Microbiol 139:2879-2889
  105. Edwards, D. I. (1980) Mechanisms of selective toxicity of metronidazole and other nitroimidazole drugs. Br J Vener Dis 56:285-290
  106. Dwyer, John J. et al. (2007) Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A 104:12772-12777
  107. Issaeva, Natalia et al. (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10:1321-1328
  108. Janssen, Katja et al. (2007) Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood 110:3662-3672
  109. Svingen, P. A. et al. (2000) Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res 6:237-249
  110. Ostrowski, M. L. et al. (1999) Malignant chondroblastoma presenting as a recurrent pelvic tumor with DNA aneuploidy and p53 mutation as supportive evidence of malignancy. Skeletal Radiol 28:644-650
  111. Giudici, D. et al. (1988) 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 30:391-394
  112. Nasr, Rihab et al. (2008) Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 14:1333-1342
  113. Galmarini, Carlos M. et al. (2002) In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 117:860-868
  114. Cline, S. D. and Osheroff, N. (1999) Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes. J Biol Chem 274:29740-29743
  115. Frankland-Searby, Sarah and Bhaumik, Sukesh R. (2012) The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta 1825:64-76
  116. Terrano, David T. et al. (2010) Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 30:640-656
  117. Fourmy, D. et al. (1996) Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274:1367-1371
  118. Krebs, Andreas et al. (2003) Targeting the HIV trans-activation responsive region–approaches towards RNA-binding drugs. Chembiochem 4:972-978
  119. Welch, Ellen M. et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87-91
  120. Goldmann, Tobias et al. (2012) A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation. EMBO Mol Med 4:1186-1199
  121. Kerem, Eitan et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372:719-727
  122. Thakral, Seema et al. (2013) Eudragit: a technology evaluation. Expert Opin Drug Deliv 10:131-149
  123. Ibrahim, Ashraf S. et al. (2003) Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 47:3343-3344
  124. Denning, D. W. and Warn, P. (1999) Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob Agents Chemother 43:2592-2599
  125. Barenholz, Yechezkel (2012) Doxil®{}—{}the first FDA-approved nano-drug: lessons learned. J Control Release 160:117-134
  126. Dedon, P. C. et al. (1993) Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry 32:3617-3622
  127. Liu, Kun et al. (2010) High-throughput screening for Kv1.3 channel blockers using an improved FLIPR-based membrane-potential assay. J Biomol Screen 15:185-195
  128. Tanino, Tetsuya et al. (2011) Mechanistic analysis of muraymycin analogues: a guide to the design of MraY inhibitors. J Med Chem 54:8421-8439
  129. McDaniel, R. et al. (1999) Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products. Proc Natl Acad Sci U S A 96:1846-1851
  130. Wang, Da-Zhi (2008) Neurotoxins from marine dinoflagellates: a brief review. Mar Drugs 6:349-371
  131. Kaplan, A. P. and Bartlett, P. A. (1991) Synthesis and evaluation of an inhibitor of carboxypeptidase A with a Ki value in the femtomolar range. Biochemistry 30:8165-8170
  132. Trott, Oleg and Olson, Arthur J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455-461
  133. Sufrin, J. R. et al. (1981) Steric mapping of the L-methionine binding site of ATP:L-methionine S-adenosyltransferase. Mol Pharmacol 19:307-313
  134. Mazzone, J. (2006) Copyfraud. New York University Law Review 81:1026-1098
  135. Rubin, Ronald P. (2007) A brief history of great discoveries in pharmacology: in celebration of the centennial anniversary of the founding of the American Society of Pharmacology and Experimental Therapeutics. Pharmacol Rev 59:289-359